Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic ...

Add Yahoo as a preferred source to see more of our stories on Google. WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), ...

Guardant Health markets Shield, an FDA-approved blood test for primary colorectal cancer screening. The Harris Poll conducted ...

SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

Landmark trials have driven a shift from radical mastectomies to less invasive, breast-conserving surgeries. Non-invasive breast carcinomas, when detected early, have highly favorable survival and ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.